RxSight (RXST) Liabilities and Shareholders Equity (2020 - 2026)

RxSight (RXST) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $352.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 14.14% year-over-year to $352.7 million; the trailing twelve-month figure through Jun 2026 stood at $1.3 billion (up 2.07% YoY), and the FY2025 full-year result was $311.8 million, down 2.12% from the prior year.
• Liabilities and Shareholders Equity advanced to $352.7 million in Q2 2026 per RXST's latest filing, from $304.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $352.7 million in Q2 2026 and bottomed at $150.2 million in Q4 2022.
• Historically, Liabilities and Shareholders Equity has averaged $246.0 million across 5 years, with a median of $253.3 million in 2023.
• The widest YoY moves for Liabilities and Shareholders Equity: up 75.7% in 2022, down 23.57% in 2022.
• Over 5 years, Liabilities and Shareholders Equity stood at $150.2 million in 2022, then rose by 21.57% to $182.5 million in 2023, then surged by 74.51% to $318.6 million in 2024, then declined by 2.12% to $311.8 million in 2025, then grew by 13.11% to $352.7 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $352.7 million, $304.0 million, and $311.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.